Clenbuterol is a sympathicomimetic agent with a predominant effect on beta 2 -adrenergic receptors [6] . In addition to its bronchospasmolytic effect it inhibits uterine contractions and has been recommended for treatment of premature labor [6] . The results of pharmacokinetic studies in nonpregnant animals [4, 7] and in nonpregnant human individuals [8] indicate rapid absorption of an oral dose of Clenbuterol by the gastro-intestinal tract, resulting in relatively high plasma levels of the unchanged compound. Elimination of orally administered isotope-labelled Clenbuterol was shown to follow a biphasic curve with a half-life of 30-35 hours in the second, slow phase [8] . If these pharmacologic properties would also be valid in pregnant women with uterine contractions, oral administration of Clenbuterol would appear to be an attractive approach to the treatment of premature labor. Therefore, the present study was designed to measure the effects of single oral doses of Clenbuterol on uterine activity äs well äs on variables of maternal and fetal cardiovascular function. The study was performed in term pregnant women with oxytocin-induced labor in order to obtain standardized uterine activity and to allow continuous measurement of in trauterine pressure and fetal heart rate.
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l Patients and methods
Informed consent for this study was obtained from ten nulliparous and fifteen parous women who received obstetric care at the AZR-Dijkzigt Clinic and had opted for elective induction of labor. The general and obstetric history of all women was negative with regard to major diseases and complications of pregnancy, and the course of the present pregnancy was uncomplicated with normal fetal growth äs confirmed by ultrasonic measurement of the fetal biparietal diameter. All women presented between 39 and 42 weeks of amenorrhea with a single fetus in the cephalic Position and a ripe cervix according to the BURNHiLL-score [1] .
l. l Induction of labor and monitoring
Labor was induced by means of low amniotomy followed by intravenous infusion of incremental doses of oxytocin. No other drugs were used except for the occasional administration of pethidine-HCl for pain relief. An open-tip catheter filled with sterile destilled water was introduced transcervically into the amniotic cavity for continuous measurement of uterine activity and a Spiral electrode (Corometrics B-2462) was attached to the fetal scalp for continuous recording of the fetal EKG and cardiotachogram. A maternal tachogram was derived from the maternal EKG and maternal blood pressure was measured between uterine contractions at 10 minute intervals with an automatic ultrasound device (Arteriosonde, Röche). All Signals were written on a multichannel polygraph and recorded on magnetic tape. [5] .
The advantage of using a 20 mm Hg level äs a reference line is that it allows sharp definition of the "onset" and the "end" of a uterine contraction. The products of intrauterine pressure and time thus calculated for.qach contraction during a period of time of 10 minutes were added and expressed äs uterine activity units (ÜAUs). Women who showed a decrease in uterine activity units of 10% or more during two consecutive periods of 10 minutes in the experimental period äs compared with the mean uterine activity in the control period were labelled "responders". Appropriate non-parametric tests were applied where necessary for statistical analysis and p < 0.05 was chosen äs the level of significance.
Results
Relevant data of the women involved in the study is summarized in Table L There were no differerices at the end of the control period between patients receiving 40, 80 or 160 ^g of Clenbuterol with regard to age, weight, duration of pregnancy, cervical dilatation and engagement of the fetal head, and uterine activity.
Effect on uterine activity
In 10 out of the 25 women uterine activity decreased following an oral dose of Clenbuterol (Tab. I). In the remaining 15 women uterine 
activity remained equal or increased during the experimental period. A decrease in uterine activity was observed in six out of ten nulliparous women, and in four out of 15 parous patients; the difference is not significant (FISHER test). The fall in uterine activity following 40 g of Clenbuterol was significantly less than that following an 80 or a 160 g dose ( Fig. 1 ), but no difference was apparent between the effect of an 80 mg and a 160 mg dose. The decrease in uterine activity äs measured in UAUs appeared to be due to a simultaneous decrease in frequency and in intensity of the contractions. The labor-inhibiting effect of Clenbuterol became apparent in all responders 30-40 minutes after oral administration, the maximum fall in uterine activity occurred after 60-80 minutes. In the 40 Mg group uterine activity in 2 of the 4 responders returned to the control level within two hours. In the remaining responders uterine activity was still significantly decreased two hours after administration of Clenbuterol. The mean duration of the first stage of labor following oral administration of Clenbuterol was 501 (ränge 140-1800) minutes in nulliparous responders, which is significantly longer than the 130 (ränge 110-400) minutes observed in nulliparous non-responders. In the parous responders the first stage of labor following Clenbuterol had a mean duration of 280 (ränge 155-495) minutes, which is significantly longer than that in the parous non-responders (mean 97 min, ränge 43-270 min). Three hours following an 80 % dose in one responder and 160 ^g in two responders uterine activity was still 50% or less ofthat in the control period. In these cases, oral administration of 40 mg of propranolol resulted in the return of adequate uterine contractions.
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Maternal and fetal cardiovascular effects
In the groups receiving 40 or 80 % of Clenbuterol no significant trend in maternal blood pressure or heart rate was observed during the experimental period.
No differences were apparent with regard to these variables between responders and non-responders.
In the three women who responded to 160 % of Clenbuterol a marked increase in heart rate was observed, which started between 40 and 60 minutes after receiving Clenbuterol. In one patient the heart rate increased to 145 beats per minute with serious palpitations, whereas systolic and diastolic blood pressure remained stable. This responder showed the greatest fall in uterine activity observed in this group. The rise in heart rate was absent in the non-responders in this group (Fig. 2) . Systolic blood pressure showed a slight increase and diastolic blood pressure feil at about 60 minutes following an oral dose of 160 ^g of Clenbuterol in responders, to an average of 80% of its baseline value. Fetal heart rate patterns remained unchanged in all cases. All infants were born alive and in good condition.
Discussion
The effect of an oral dose of Clenbuterol on uterine activity in parturient women in the begining of the first stage of labor appears to be variable: in 60% of our patients no effect at all was seen, whereas uterine activity was clearly inhibited in the remaining 40%.
In the responders the decrease in uterine activity was less marked with a 40 μg dose than with 80 or 160 μg of Clenbuterol. Since no difference was apparent between the degree of myometrial Inhibition obtained with 80 //g and that following 160 Mg, 80 Mg of Clenbuterol appears to be an optimal oral dose. All responders show a similar pattern of Inhibition of myometrial activity: labor activity begins to decrease 30-40 minutes after oral administration of Clenbuterol, and a maximum fall in uterine activity is observed after 60-80 minutes, followed by a gradual increase in frequency and intensity of uterine contractions. The effect of Clenbuterol appears to be long-lasting: uterine activity was still significantly reduced two hours after oral administration in all responders except in two patients who received a 40 Mg dose. Our finding that more than half the number of women studied did not respond at all might be attributed to absent or inadequate intestinal absorption of the agent due to delayed gastric emptying in these cases. Clenbuterol is absorbed by the intestinal tract and it is known that gastric emptying often stops completely during labor [2] . Because a plasma assay of Clenbuterol was not available we were unable to adduce direct evidence to support or refute this hypothesis.
The absence of significant differences in cervical dilatation, engagement of .the presenting part, and baseline uterine activity at the time of administration of Clenbuterol between responders and nonresponders makes it unlikely that the variability of the response to Clenbuterol could be due to differences in the degree of labor. Effects of Clenbuterol on maternal blood pressure and heart rate were apparent in all responders who received 160 Mg of Clenbuterol, but were absent in the non-responders, which lends indirect support to the hypothesis of poor absorption in these cases. Maternal tachycardia was observed to Start earlier than the fall in diastolic blood pressure, and it was still present when diastolic blood pressure had returned to its control value. This suggests a direct positive chronotropic effect of Clenbuterol on the maternal heart, but the limited number of observations precludes firm conclusions in this respect.
Although Clenbuterol has been shown to be transferred across the placenta in animal experiments [4] we observed no effect on fetal heart rate, even not in women who responded to an oral dose of 160 Mg.
In conclusion, an oral dose of 80 Mg of Clenbuterol appears to inhibit uterine activity effectively and with virtually no side effects during a period of time of more than two hours, provided that it is absorbed from the intestinal tract. However, intestinal absorption is known to be variable during labor due to the delay in gastric emptying. For this reason and also because of the relatively delayed onset of action, oral administration of Clenbuterol cannot be recommended for acute treatment of premature labor. However, it could be an attractive approach to maintenance of therapy once uterine contractions have been effectively inhibited by means of an intravenously administered sympathicomimetic agent, or to prevention of threatened premature labor.
Summaiy
The effects of a single oral dose of the beta-sympathicomimetic agent Clenbuterol on uterine activity and maternal and fetal cardiovascular variables were experimentally investigated in 25 women in the first stage of oxytocininduced labor. Intra-amniotic pressure, and fetal and maternal heart rate were continuously recorded, and maternal blood pressure was measured with an ultrasound device at 10 minute intervals. Myometrial contractility was expressed in uterine activity units (UAUs). After stable uterine activity of between 80 and 110 UAUs was
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obtained, an oral dose of 40, 80, or 160 Mg of Cienbuterol was given. In 10 women uterine contractionsdecreased following a single oral dose of Cienbuterol (responders), whereas in the remaining 15 women no effect on myometrial activity was observed (non-responders). In responders the fall in uterine activity following a 40 Mg dose was significantly less than that following an 80 or 160 Mg dose, but the difference between 80 and 160 Mg was not significant. In all responders the labor-inhibiting effect of Cienbuterol became apparent 30-40 minutes following oral administration, and the maximum decrease in uterine activity occurred after 60-80 minutes. Except in women who received 40 Mg, the effect lasted at least 2 hours in all responders. An increase in maternal heart rate together with a rise in systolic blood pressure and a slight fall of the diastolic pressure were observed in responders who received 160 Mg of Cienbuterol but were absent in the other responders. Effects on fetal heart rate were never demonstrated. The absence of a response even to a high dose of Cienbuterol in 15 out of 25 women in early labor might be attributed to absent or inadequate intestinal absorption of the agent due to delayed gastric emptying which is known to occur during labor. On the basis of these findings we conclude that oral administration of Cienbuterol cannot be recommended for acute treatment of premature labor but could be an attractive approach to maintenance of therapy once uterine contractions have been effectively inhibited by means of an intravenously administered sympathicomimetic agent, or to prevention of threatened premature labor.
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